AFM
ARCT icon

Anson Funds Management’s Arcturus Therapeutics ARCT Stock Holding History

Anson Funds Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,425
Closed -$300K – 52
2016
Q4 		$300K Buy
+20,425
New +$305K 0.09% 54

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Anson Funds Management's ARCT Position: Q1 2017 in Review

Anson Funds Management sold out of Arcturus Therapeutics (ARCT) in Q1 2017, closing a stake of 20,425 shares — an estimated $300K sold.

Anson Funds Management first reported a position in ARCT in Q4 2016 and held it in 1 quarter. The position peaked at $300K in Q4 2016. 33 funds tracked by Wall St. Rank hold ARCT as of Q1 2017.

  • Anson Funds Management reported no remaining Arcturus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Anson Funds Management sold 20,425 Arcturus Therapeutics shares in Q1 2017, an estimated $300K.
  • Anson Funds Management first reported a position in Arcturus Therapeutics in Q4 2016 and held it in 1 quarter.
  • Anson Funds Management's Arcturus Therapeutics position peaked at $300K in Q4 2016.
  • 33 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.